Amyloid Precursor Protein Processing and Alzheimer’s Disease
Neuroscience

Amyloid Precursor Protein Processing and Alzheimer’s Disease


An NIH Public Access Author Manuscript:

Richard J. O’Brien and Philip C. Wong
Amyloid Precursor Protein Processing and Alzheimer’s Disease
Published in final edited form as:
Annu Rev Neurosci. 2011 ; 34: 185–204. doi:10.1146/annurev-neuro-061010-113613.

Download the free-access pdf here

This looks like a fine overview of our current knowledge.




- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...

- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...

- Alzheimer's: Impaired Beta-amyloid Clearance
From the NIH: Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease 09 December 2010 In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers...

- Alzheimer's Disease: Amyloid Jitteriness
A Bloomberg News report about the state of clinical trials of those Alzheimer's disease candidates in the processes/stages in amyloid levels and amyloid deposition: read article here...

- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...



Neuroscience








.